SymBio Pharmaceuticals (TSE:4582) Other Current Liabilities: 円21 Mil (As of Dec. 2025)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

TSE:4582 SymBio Pharmaceuticals Ltd TSE:4582
35 GF Score
Price 円70.00
GF Value 円60.49
Valuation Modestly Overvalued
! 6 Warning Signs
View Full Analysis

What is SymBio Pharmaceuticals Other Current Liabilities?

SymBio Pharmaceuticals TSE:4582 -1.41% 35 Other Current Liabilities is 円21 Mil as of Dec. 2025. GuruFocus rates TSE:4582 with a GF Score™ of 35/100 and a GF Value™ of 円60.49 (Modestly Overvalued). The stock has 6 warning signs investors should review.

SymBio Pharmaceuticals's other current liabilities for the quarter that ended in Dec. 2025 was 円21 Mil.

SymBio Pharmaceuticals's quarterly other current liabilities declined from Jun. 2025 (円32 Mil) to Sep. 2025 (円24 Mil) and declined from Sep. 2025 (円24 Mil) to Dec. 2025 (円21 Mil).

SymBio Pharmaceuticals's annual other current liabilities declined from Dec. 2023 (円84 Mil) to Dec. 2024 (円28 Mil) and declined from Dec. 2024 (円28 Mil) to Dec. 2025 (円21 Mil).

SymBio Pharmaceuticals Other Current Liabilities Related Terms

SymBio Pharmaceuticals Other Current Liabilities Historical Data

* Premium members only.

The historical data trend for SymBio Pharmaceuticals's Other Current Liabilities can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

SymBio Pharmaceuticals Other Current Liabilities Chart

SymBio Pharmaceuticals Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Other Current Liabilities
Get a 7-Day Free Trial Premium Member Only Premium Member Only 33.72 312.45 84.33 28.31 21.04

SymBio Pharmaceuticals Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Other Current Liabilities Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 49.61 32.07 24.32 21.04 136.24
TSE:4582
35GF Score
SymBio Pharmaceuticals Ltd TSE:4582
Other Current Liabilities is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

SymBio Pharmaceuticals Other Current Liabilities Calculation

The liability a company needs to pay in the next 12 months, but not assigned to Accounts Payable or Debt. For instance, Wal-Mart (WMT) has accrued wages, salaries, valuation, bonuses, insurance liabilities, accrued tax etc. These are all included in other current liabilities.

What does a Other Current Liabilities of 円21 Mil mean?
SymBio Pharmaceuticals (TSE:4582) has a Other Current Liabilities of 円21 Mil as of Dec. 2025. Other current liabilities as record on a company's balance sheet not categorized as standard liabilities. View historical data on SymBio Pharmaceuticals.
Is SymBio Pharmaceuticals' Other Current Liabilities too high?
SymBio Pharmaceuticals' current Other Current Liabilities is 円21 Mil. Overall, SymBio Pharmaceuticals has a GF Score™ of 35/100 and is considered Modestly Overvalued, reflecting its overall financial health beyond just this single metric.
How does SymBio Pharmaceuticals' Other Current Liabilities compare to ZTS and UTHR?
SymBio Pharmaceuticals' Other Current Liabilities of 円21 Mil can be compared against companies in the Drug Manufacturers industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Other Current Liabilities for a Drug Manufacturers company?
A good Other Current Liabilities depends on the Drug Manufacturers industry context. However, Other Current Liabilities should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Other Current Liabilities mean?
A high Other Current Liabilities can signal that a stock is expensive relative to its fundamentals. Other current liabilities as record on a company's balance sheet not categorized as standard liabilities. View historical data on SymBio Pharmaceuticals. SymBio Pharmaceuticals's current Other Current Liabilities is 円21 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is SymBio Pharmaceuticals stock overvalued right now?
Based on GuruFocus' analysis, SymBio Pharmaceuticals (TSE:4582) is currently considered Modestly Overvalued. The stock's GF Value™ is 円60.49, compared to a current price of 円70.00 — trading 15.7% above its estimated fair value. The current Other Current Liabilities is 円21 Mil. SymBio Pharmaceuticals' overall GF Score™ is 35/100 with 6 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Other Current Liabilities calculated?
Other Current Liabilities is calculated from a company's financial statements. For SymBio Pharmaceuticals (TSE:4582), the current Other Current Liabilities is 円21 Mil as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is SymBio Pharmaceuticals (TSE:4582) Overvalued in 2026?

Based on GuruFocus' analysis, SymBio Pharmaceuticals stock appears to be overvalued. The current stock price of 円70.00 is trading 15.7% above its estimated GF Value™ of 円60.49. GuruFocus considers SymBio Pharmaceuticals to be Modestly Overvalued.

Key valuation signals for TSE:4582:

  • Other Current Liabilities: 円21 Mil
  • GF Value™: 円60.49 vs. price of 円70.00 (15.7% above fair value)
  • GF Score™: 35/100 with 6 warning signs

No single metric tells the full story. See the TSE:4582 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

SymBio Pharmaceuticals Business Description

Address 1-28 Toranomon 4-chome, 7th Floor, Toranomon Towers Office, Minato-ku, Tokyo, JPN, 105-0001
SymBio Pharmaceuticals Ltd is a biopharmaceutical company engaged in development of new drugs with a primary focus on the treatment of rare diseases, mainly in the areas of oncology, hematology and multiple viral infections, and conduct integrated business activities that encompass search for new drug candidates, development, manufacturing, and sales.
35GF Score

Get the complete analysis for TSE:4582

Other Current Liabilities is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

円70.00
Price
円60.49
GF Value